GWM
PCRX icon

Gilpin Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Gilpin Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229 Sell
9
-1
-10% -$24 ﹤0.01% 883
2026
Q1 		$226 Buy
10
+8
+400% +$178 ﹤0.01% 833
2025
Q4 		$52 Buy
+2
New +$48 ﹤0.01% 947

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilpin Wealth Management's PCRX Position: Q2 2026 in Review

Gilpin Wealth Management reduced its Pacira BioSciences (PCRX) stake by 10% in Q2 2026, selling an estimated $24 and leaving 9 shares worth $229. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Gilpin Wealth Management first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. 252 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Gilpin Wealth Management held 9 shares of Pacira BioSciences worth $229 as of Q2 2026.
  • Gilpin Wealth Management sold 1 Pacira BioSciences share in Q2 2026, an estimated $24.
  • Pacira BioSciences made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q2 2026, its #883 holding.
  • Gilpin Wealth Management first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
  • 252 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.